more you and be you you, to strong well to way. Thank pick on not Marc. Veracyte go. in we where continue XXXX, taking excited the our progress aspire to performance partner could first the with And up with of quarter and we torch are I the as
to especially first practices country open our delivered momentum quarter to the solid Turning as continue increased vaccination up. in COVID physician performance, we and robust with results March rates across
quarter genomic XX,XXX revenue in was over quarter, XX% total quarter XXXX. increase and was our of an the prior of XX% product first tests the first $XX.X volume for Our the million, an increase testing over year. And
of guidance our million results, are $XXX $XXX we million. solid total revenue to year XXXX With these reiterating full
We to of reach contributing our top Decipher to traction. and well. acquisition already prostate our family. are which States team our test, to The Decipher from and revenue into in going cancer its learning Biosciences with integration and are other. Top welcome business really March each the XX the already is X their the Veracyte collaborating notch commercial teams cancers gain expands thrilled is complete United continues on The of strong XX And
are launch new changer noninvasive great in half to potentially which Percepta of more novel in These year. nasal believe pulmonology and our is game detection, to the include on be our We to pipeline early also in in track be we the saved. a lives products test, second made lung progress enabling swab going advancing X cancer
the excited validation data meeting unveil to ASCO test half annual upcoming its of are to for at prior clinical year. the launch pivotal the We planned second in the
key I’ll Now commercial quarter. our first the highlights for with first of measure let’s success. growth, start review
XX% prostate The million, over and $XX.X testing growth of of the first driver revenue was of increase XXXX. genomic primary Our the addition was an the of quarter volume. the product Decipher
of unique in grew fact, of physician our and franchise over by primarily as leading revenue majority recovery urologic with among X% our we with in business, of cancer as Decipher our is Decipher, million, nearly our XXXX, reps. respectively. physicians vast highs physicians increasingly physicians, our represented tests and number patients both to about ordering offices our $XX.X driven experienced accessible to Afirma of Afirma the monthly X,XXX thyroid sales testing volume cancer. March well Office-based legacy in Afirma Excluding pandemic XX% prostate for the all-time and Afirma in X,XXX our
business in by physician for well as cancer Afirma We at of of growth diagnosis. to space. to our franchise in be is evaluation care the comprehensive offer cancerous further biomarker with long-term positioned for franchise Our we fueled the genomic expression extensively profiling as the nodule time decipher thyroid continues validated information the new product prostate and thyroid believe we genomic believe the best momentum most modules standard continues gain in what to provide adoption interest our Atlas on
in target for physician that a United indications are expanded also including and over indications from call and practicing sales X,XXX high-risk Medicare XXXX States. in reps the our coverage benefiting point, radiation We new oncologists to late the for high allow new very decisions
to pace, slower side, rebound, the although our the still at pandemic of On business limiting with a Percepta performed. number continues and pulmonology being the Envisia
analysis As evidenced, levels. at claims pre-pandemic overall that volumes bronchoscopy research our XX% are shows
to increases compared too, though, and February. January test saw volume we Here significant in March
learned addition access gaining we the digital approach tools, to physician a continuing of that our our increased are pandemic. to during In highly we engagement to use marketing grow customers, effective
all-time physician online sponsored participation drove a KOLs, our targeted their of marketing of number active our websites series webinar as online products first the that here efforts an than as in product well communities XXX,XXX in include and use leading featuring more peer-to-peer visits quarter, high. Our to discussing
our significant well offering also advancement, in will We our as expand progress reach. and of breadth which pipeline made as depth global the
important objective detection, annual tools our are We for test excited with to data nasal bring will lack lung on Percepta and physicians June. The be annual potentially now validation U.S. directed cancerous screening wake We conjunction routine clinical ASCO to to can in for in much believe swab for million. is upcoming estimated lung eligible cancer of especially to swab nasal today, need especially that preventative be better number our force test the virtually the in evaluation, safely with determine clarity CT tool early nodules cancer pivotal XX a CT task where service to need is monitoring. which needed unveil patients going to the recommendations meeting, found new lung further held cancer which people an which of in expand
an global accessing franchise. to track half nCounter swab to of for nasal in analysis evidence cancer coverage. in on our we number needed we it adapt nasal to approximately we market second believe to program $X access clinical enable to launch are the which will begin billion as the early we of us Moreover, We XXXX, test system Medicare plan lung which at a make to test the obtain XXXX, sites through the an point, available our amass swab select utility will
natal Percepta Atlas, later in inappropriate treatment profiling for have information a also typically comprehensive often Currently, transthoracic which workup the that using process, a the to used will diagnosis. information tiny is this decisions which from bronchoscopy physicians was us We aspiration to treatment. a biopsy same provided leads advanced tumor our Genomic delayed or enabling inform or with lung provide in cancer genomic patient’s
and portfolio. American the at of share to test of and on in quarter annual cancer our XXXX new lung will ATS, fourth of the comprehensive Perceptive We Society, the data introduce Oncology, commercially Society Genomic or part or the ASCO, Atlas meetings upcoming Clinical American as Thoracic plan
nCounter or test lung patients to We the for help ATS for the markets. We target instrument the local market global us on development conference Mark shaping interstitial and this the CE with on KOLs the support clinical Europe the access engaging to for the also initiated our nCounter year, prognosis will help diseases later improve We’ve classifier utility at to in test look launched performance When in advanced of identifying this on unveil to forward Envisia of analysis plan studies decisions. diagnosis enable system. inform focused in test by and regarding of market the year. activities submitting the end data and countries
also made have our market medical key access in We hires support our efforts. and functions to
initial installed current secure launch and help base market for fast our leveraging customers are to the access. We
global our planned which with has made we the where our of on quarter. platform, will Veracyte-branded become at more of focus significant anticipated diagnostics-only growth expansion support I initiated in time our nCounter with during we Additionally, strategy, the our development, the had we on the development of evidence menu system. which transaction NanoString progress also timely next and
ASCO. accepted testing that genomic cancers excited are for at and We in lung, our been have X prostate thyroid for presentations abstracts
in in genomics. and shows In the alone podium need prostate inadequacy addition classification the test to VANDAAM data our of Decipher prospective a men African-American from cancer validation the lung of data clinical subsequent for which products, risk participation these our for portfolio study is a include for the presentation and
Our participation deepen with institutions clinical record, in academic continued will the our cancer over and in with continue partnership prostate worldwide key our along publication long-term. trials, leadership many to track
the aspiration decisions time treatments that new also to thyroid Atlas’ or needle in comprehensive demonstrating data new plan regarding in genomic targeted in-treatment of fine identify may at at We to Thyroid information share form Xpression This available development. our ASCO samples. cancer diagnosis Afirma ability are alterations
I abstracts at Envisia for a this focused mentioned the also performance will earlier, where classifier. addition robust the week, showing We pipeline be ATS conference have significant later our four data in to presented, presence data
data to own the regarding with We their leading UCLA begin see such as to experience test. are report institutions pleased
Medical Society of ESMO first genomic including Conference, PROCURE. about findings consensus are to Finally, the Delphi European at and Oncology, initial utilizes also this the tests, of presentation month or we Cancer utility clinical Breast of the wave excited European generate study This Prosigna. the of methodology on from consensus
related presented signature this on You practicing recall input is scientific XXXX Slide the data well over X. refer address of decision-making Prosigna, cancer from My of independent range. cancer breast to begin study, website. that PAMXX $XXX our committee our content experts breast now until review at XXX will XXXX that revenue business includes our XX% Europe. financial breast by clinicians line ESMO as is available led I breast of patients which the evaluating Slide mentioned Also and with being influence financial a meeting. study an reflects our With assay. our I the total remarks foundation of early-stage on to to at will $XXX on the the throughout will financials. and presentation, for X, cancer the quarter growth will therapeutic and the approximately signature is The turn the quarter gene first now billion cancer, prospective those the I PAMXX are prepared Prosigna billion, first approximately X a detailed more with insights, expectations from year key representing other which which to XXXX is Tracy through as of midpoint earlier full review top of over of takeaways
quarter specifically, the quarter first to increase an generated XXXX million Turning quarter. total right over XX, we $XX.X revenue, column the – XX% of in prior slide, the hand prior year of Slide revenue for through XXXX. closed million and the $XX.X We XX, consequently, $X.X revenue of XX Biosciences March in period March of includes XX Decipher million March and our the acquisition testing urology on
which the XX-Q detail further on file our today, expect includes to acquisition. We Form
genomic over of quarter XXXX, for Turning urology for XXXX. XX. was compared volume to portfolio Percepta the reported Afirma, quarter. quarter X,XXX urology an Decipher This GSC the volume tests XX,XXX, quarter, increase XX XX,XXX our of an prior year XX reported excluding Envisia we per first And the X% test, XX% of and the includes March through in and of our increase from the testing first Slide to across tests
X,XXX mid Our XX expenses. been volume over performance against indicators Decipher operating shows the In will and margins of acquisition-related XXXX, and expenses our a These first for point the and a of in revenue. first and volume decline the period. year product tests well the prior total product our expenses. expense XXXX, that as percent and XX The quarter quarter dollars million per general quarter as increase which X% as Prosigna quarter historical Slide XX of XX% biopharma and Slide level was $X,XXX, million including in of marked which down into approximately biopharma Slide Decipher breaking Prosigna revenue, post are out first key included the of XX XXXX shows XXXX. year represents had in expenses against collaboration to our the increase, the I recorded average revenue. our the the of XX% stock Slide $XX.X and of range. awards. transaction a We fees, from six first XX and volume provided legal $XX.X results a to a expenses of settlement year-over-year. revenue. sequential first testing quarter and Decipher first Gross Biosciences margins banking for following acquisition. in but shows we product without revenue for million nonrecurring gross compared unvested test shown $XX.X test with quarter in dollars XX% testing, remain XXXX expense, period. quarter administrative record and incurred of in revenue million collaboration and acquisition-related absolute prior operating revenue include acceleration and absolute $XX quarter in which the digs deeper related the our in costs, a XX into reported combination cost Slide trends cash performance our sequential
Excluding principally were and the The marketing from is increase sales an million $XX.X in acquisition-related sequential expenses expenses, our quarter. for operating expenses. increase
quarter, at operating administrative With year. the to the of expenses $XX trends asset we sales of our R&D $XX.X in we to $X expense million intangible per these million quarterly for ranges and we million XX first operations. loss would be I as in or flow ramp G&A nonrecurring to million, this acquisition-related recorded paid expenses onetime the from our quarter following acquisition to of cash items the incurred the cash quarter expect per Decipher, excluding remainder XX from to of the net second quarter. million operations marketing per $XX XXXX, in our the and earlier, to in million million in $XX from expenses. quarter, mentioned quarter, and to which and $XX $X.XX million $XX to any reducing fourth quarter, by $X We range million general amortization in to $XX from in show first flow Slides expenses
with the wish Veracyte our next progress financial to success. during million his in which a X-year believe will on him shown tenure contributions ended XX, after on company. hand for we costs, As Keith and and for strong I building ensure would infrastructure including quarter the played like interest-bearing on his paying to his In XX, associated cash continued material our closing, Kennedy an all We chapter. Decipher the help Slide acquisition we in team, of $XXX outstanding. March no best important role XXXX, debt He many with and thank
reflects so forward, we foundation progress robust have built Looking believe strong in far the that our to date. I XXXX
the are that the this every backbone to our We as for their and in CEO step will joining strategic Marc patients the other of all world new is vision fortunate diseases. be over journey outcomes success, global of build that powerful cancer improving upon at
estimated to open us company Deliver committed into penetration is I ask billion-plus are we Veracyte and and phase what that, questions. am call acquisition the forward. the on to he exclusive long-term the will continue the And supporting the With diagnostics, Marc tests. of now is leads our access for for system the fully growth. excited I operator And for for set well $XX market for next positioned the table to the next as execute to with our nCounter to of for analysis our
